Literature DB >> 10838497

Relative expression of the RET9 and RET51 isoforms in human pheochromocytomas.

H Le Hir1, N Charlet-Berguerand, A Gimenez-Roqueplo, M Mannelli, P Plouin, V de Franciscis, C Thermes.   

Abstract

Activating mutations of the RET oncogene cause the inheritance of multiple endocrine neoplasia type 2 (MEN2). The RET pre-mRNA is spliced into several transcripts coding for multiple isoforms, including Ret9 and Ret51. When harboring activating mutations in the cytoplasmic region, the Ret51 protein displays a higher in vitro transforming efficiency as compared to the corresponding Ret9 isoform. We investigated whether a more transforming isoform was preferentially expressed in MEN2 tumors as compared to normal tissues or sporadic pheochromocytomas. By quantitative RNases protection assays, we measured the absolute abundance of the 3' splice variants in pheochromocytomas and in normal tissues. The proportion of RET51 transcripts was highly dispersed between tumors and normal tissues. In familial tumors the proportion of RET51 transcripts was significantly larger (48.1%) than in sporadic tumors (36.75%). This result suggests that the preferential expression of the Ret51 protein isoform, even though moderate, is a growth advantage for MEN2 tumors. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10838497     DOI: 10.1159/000012118

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  11 in total

1.  GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion.

Authors:  Mathieu J F Crupi; Sarah M Maritan; Eduardo Reyes-Alvarez; Eric Y Lian; Brandy D Hyndman; Aisha N Rekab; Serisha Moodley; Costin N Antonescu; Lois M Mulligan
Journal:  Oncogene       Date:  2019-10-23       Impact factor: 9.867

2.  Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas.

Authors:  Teresa Ramone; Cristina Romei; Raffaele Ciampi; Alessia Tacito; Paolo Piaggi; Liborio Torregrossa; Clara Ugolini; Rossella Elisei
Journal:  Endocrine       Date:  2019-07-05       Impact factor: 3.633

3.  Multiple Roles of Ret Signalling During Enteric Neurogenesis.

Authors:  Dipa Natarajan; Conor McCann; Justine Dattani; Vassilis Pachnis; Nikhil Thapar
Journal:  Front Mol Neurosci       Date:  2022-05-27       Impact factor: 6.261

4.  Ret protein expression in adrenal medullary hyperplasia and pheochromocytoma.

Authors:  James F Powers; Jaime M Brachold; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 5.  RET signaling in endocrine tumors: delving deeper into molecular mechanisms.

Authors:  Andrea Z Lai; Taranjit S Gujral; Lois M Mulligan
Journal:  Endocr Pathol       Date:  2007       Impact factor: 3.943

6.  Adrenergic differentiation and Ret expression in rat pheochromocytomas.

Authors:  James F Powers; Kristen L Picard; Abraham Nyska; Arthur S Tischler
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

Review 7.  State-of-the-Art Strategies for Targeting RET-Dependent Cancers.

Authors:  Vivek Subbiah; Dong Yang; Vamsidhar Velcheti; Alexander Drilon; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

8.  Alternative splicing results in RET isoforms with distinct trafficking properties.

Authors:  Douglas S Richardson; David M Rodrigues; Brandy D Hyndman; Mathieu J F Crupi; Adrian C Nicolescu; Lois M Mulligan
Journal:  Mol Biol Cell       Date:  2012-08-08       Impact factor: 4.138

9.  Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.

Authors:  Mi-Sook Lee; Ryong Nam Kim; Hoseok I; Doo-Yi Oh; Ji-Young Song; Ka-Won Noh; Yu-Jin Kim; Jung Wook Yang; Maruja E Lira; Chang Hun Lee; Min Ki Lee; Yeoung Dae Kim; Mao Mao; Joungho Han; Jhingook Kim; Yoon-La Choi
Journal:  Oncotarget       Date:  2016-06-14

10.  A rare haplotype of the RET proto-oncogene is a risk-modifying allele in hirschsprung disease.

Authors:  Paola Griseri; Barbara Pesce; Giovanna Patrone; Jan Osinga; Francesca Puppo; Monica Sancandi; Robert Hofstra; Giovanni Romeo; Roberto Ravazzolo; Marcella Devoto; Isabella Ceccherini
Journal:  Am J Hum Genet       Date:  2002-09-04       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.